tailieunhanh - Báo cáo y học: " Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial"

Tuyển tập các báo cáo nghiên cứu khoa học ngành y học tạp chí Medical Sciences dành cho các bạn sinh viên ngành y tham khảo đề tài: Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. | Int. J. Med. Sci. 2009 6 312 International Journal of Medical Sciences 2009 6 6 312-321 Ivyspring International Publisher. All rights reserved Research Paper Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee a clinical trial David C. Crowley1 Francis C. Lau2 Prachi Sharma1 Malkanthi Evans1 Najla Guthrie1 Manashi Bagchi2 Debasis Bagchi2 3 Dipak K. Dey4 Siba P. Raychaudhuri 5 6 M 1. KGK Synergize Incorporated London ON Canada 2. Department of Research and Development InterHealth Research Center Benicia CA USA 3. Department of Pharmacology and Pharmaceutical Sciences University of Houston College of Pharmacy Houston TX USA 4. Department of Statistics University of Connecticut Storrs CT USA 5. Department of Medicine Division of Rheumatology Allergy and Immunology School of Medicine University of California Davis Davis CA USA 6. VA Medical Center Sacramento Hospital Way Mather CA USA ISI Correspondence to Siba P. Raychaudhuri sraychaudhuri@ Received Accepted Published Abstract Previous studies have shown that undenatured type II collagen UC-II is effective in the treatment of rheumatoid arthritis and preliminary human and animal trials have shown it to be effective in treating osteoarthritis OA . The present clinical trial evaluated the safety and efficacy of UC-II as compared to a combination of glucosamine and chondroitin G C in the treatment of OA of the knee. The results indicate that UC-II treatment was more efficacious resulting in a significant reduction in all assessments from the baseline at 90 days whereas this effect was not observed in G C treatment group. Specifically although both treatments reduced the Western Ontario McMaster Osteoarthritis Index WOMAC score treatment with UC-II reduced the WOMAC score by 33 as compared to 14 in G C treated group after 90 days. Similar results were obtained for visual analog scale VAS scores. Although both the treatments reduced